Trial Profile
An Open Study With OXN to Evaluate the Patient Preference for Pain Treatment With Respect to Quality of Life After WHO Stap I or Step II Analgesics for Patients With Moderate to Severe Non-malignant Pain
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Oxycodone/naloxone (Primary)
- Indications Pain
- Focus Therapeutic Use
- Acronyms PREFER
- Sponsors Mundipharma CVA
- 04 Jul 2012 Planned number of patients changed from 180 to 215 as reported by European Clinical Trials Database (EudraCT2008-001026-14).
- 21 Jul 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health record NCT01167699).
- 21 Jul 2010 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.